consensus guidelines on practical issues of immunotherapy-canadian society of allergy and clinical immunology (csaci)共识指南的实际问题immunotherapy-canadian变态反应与临床免疫学协会(csaci).pdfVIP

Original Article Consensus Guidelines on Practical Issues of Immunotherapy–Canadian Society of Allergy and Clinical Immunology (CSACI) Eric Leith, MD; Tom Bowen, MD; Joe Butchey, MD; David Fischer, MD, FRCPC; Harold Kim, MD, FRCPC; Bill Moote, MD, FRCPC; Peter Small, MD; Don Stark, MD, FRCPC; Susan Waserman, MD The Canadian Society of Allergy and Clinical lin E (IgE). When a multivalent allergen binds its Immunology (CSACI) guidelines for the use of specific IgE, the high-affinity receptors are cross- allergen immunotherapy were first published in linked, leading to a cascade of events that result 1995; since then, updated guidelines have been in mast cell and basophil degranulation. The result- published.1–3 The CSACI has reviewed this topic ing mediators and growth factors are also associ- at its annual meetings and in its official publica- ated with the late-phase allergic response and with tion.4 We hope that this “Consensus Guidelines on chronic inflammation. Eosinophils and neutrophils Practical Issues of Immunotherapy” will promote are attracted by chemotactic factors to the site of excellence in the practice of immunotherapy in an immediate hypersensitivity reaction; in chronic Canada. (“Allergen immunotherapy” or “specific allergic reactions, mononuclear cell infiltrates are immunotherapy” has also been termed “allergen also found. The inflammatory response has features vaccine” by the World Health Organization and of cellular and humoral immunity, and it results others.5,6) from a network of interacting soluble mediators, cytokines, and chemokines.7 Immunoglobulin E–Mediated Immune Response